SK
Sekar Kathiresan
Chief Executive Officer

Sekar Kathiresan insider trades: Verve Therapeutics (VERV) stock buys and sales

Chief Executive Officer, Verve Therapeutics Last trade Apr 2, 2025 22 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2021
3
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Sekar reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Apr 2, 2025VERV↓ Sell$41K
Oct 3, 2022VERV↓ Sell$1.7M
Aug 10, 2022VERV↓ Sell$1.5M
Jul 19, 2022VERV↓ Sell$1.5M
Jan 4, 2022VERV↓ Sell$75K
Dec 28, 2021VERV↓ Sell$2.0M
Dec 23, 2021VERV↓ Sell$4.5M
Jun 21, 2021VERV↑ Buy$48K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Sekar Kathiresan's insider trades

Sekar Kathiresan is Chief Executive Officer at Verve Therapeutics (VERV). Since Jun 21, 2021, Sekar has reported 1 open-market purchase worth $48K and 7 sales worth $11.2M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (10 filings), option exercises (9 filings), gifts (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VERV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.